LIMKi 3

• Supplier: Tocris Bioscience
• Catalog: 3057
• Prices: $199.00
• Sizes: 10 mg
• Function Type: Inhibitor
• Cas Number: 1338247-35-0
• Chemical Name: N-[5-[1-(2,6-Dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-2-thiazolyl]-2-methylpropanamide
• Formula: C17H14Cl2F2N4OS
• Molecular Weight: 431.29
• Purity: >98 %
• Description: Potent LIM kinase inhibitor (IC 50 values are 7 and 8 nM for LIMK1 and LIMK2 respectively). Inhibits cofilin phosphorylation in MDA-MB-231 breast cancer cells. Reduces MDA-MB-231 tumor cell invasion in a 3D matrigel invasion assay.

Product References

Identification of a nonkinase target mediating cytotoxicity of novel kinase - Identification of a nonkinase target mediating cytotoxicity of novel kinase

Ross-Macdonald P, de Silva H, Guo Q, Xiao H, Hung CY, Penhallow B, Markwalder J, He L, Attar RM, Lin TA, Seitz S, Tilford C, Wardwell-Swanson J, Jackson D. Mol Cancer Ther. 2008 Nov;7(11):3490-8.

LIM kinases are required for invasive path generation by tumor and - LIM kinases are required for invasive path generation by tumor and

Scott RW, Hooper S, Crighton D, Li A, Konig I, Munro J, Trivier E, Wickman G, Morin P, Croft DR, Dawson J, Machesky L, Anderson KI, Sahai EA, Olson MF. J Cell Biol. 2010 Oct 4;191(1):169-85.

The actin-severing protein cofilin is downstream of neuregulin signaling and is - The actin-severing protein cofilin is downstream of neuregulin signaling and is

Sparrow N, Manetti ME, Bott M, Fabianac T, Petrilli A, Bates ML, Bunge MB, Lambert S, Fernandez-Valle C. J Neurosci. 2012 Apr 11;32(15):5284-97.